RedHill Biopharma Ltd. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Last price 0.4166 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Details
| Name | RedHill Biopharma Ltd. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 13 |
| Founded | 2009 |
| Ceo | Dror Ben-Asher |
| Country | Israel |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US7574683014 |
| Cusip | 757468301 |
| Cik | 0001553846 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dror Ben-Asher | Co-Founder, Chairman and Chief Executive Officer |
| Razi Ingber | Chief Financial Officer |
| Gilead Raday MPhil, MSc | Chief Operating Officer |
| Adi Frish | Chief Corporate and Business Development Officer |
| Rick D. Scruggs | Chief Commercial Officer and Director |
| Dr. Mark L. Levitt M.D., Ph.D. | Chief Scientific Officer |
| Alexandra Okmian | Senior Business Development and Investor Relations Manager |
| Dr. Reza Fathi Ph.D. | Senior Vice President of Research and Development |
| Guy Goldberg J.D. | Chief Business Officer |
| Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs |
Contact
| Address | 21 Ha’arba’a Street, Tel Aviv-Yafo, 6473921, Israel |
| Phone | 972 3 541 3131 |
| Website | https://www.redhillbio.com |